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maximal uncoupled respiration, especially in the presence of calcium,
suggesting that a full Ca2+-dependent activation of aralar–MAS is
required under this condition. On the other hand, SCaMC-3 has no effects
on basal or maximal respiration aids in maintaining a higher and more
sustained respiration under conditions of mitochondrial Ca2+ overload.
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Metformin is a widely prescribed drug used for the treatment of
type 2 diabetes. Previous studies have demonstrated that metformin
speciﬁcally inhibits complex I of the mitochondrial respiratory system
[1,2]. This seems counterproductive since impaired muscle mito-
chondrial function has been linked to the pathogenesis of type 2
diabetes [3,4].
Objective: To investigate the effects of metformin on in vivo and in
vitro skeletal muscle mitochondrial function in Zucker diabetic fatty
(ZDF) rats using 31P magnetic resonance spectroscopy (MRS) and
high-resolution respirometry (HRR), respectively.
Methods: 12-week old healthy (fa/+) and diabetic (fa/fa) ZDF rats
were treated with metformin (0, 30, 100 or 300 mg/kg body weight/
day) for 15 days by oral gavage. At day 14, 31P MRS was performed
on the tibialis anterior (TA) muscle to determine mitochondrial
function in vivo. A time series of 31P spectra was measured before,
during and after muscle contractions to measure PCr recovery rate,
which is an indirect measure of mitochondrial function in vivo.
Muscle contractions were induced by electrical stimulation of the TA,
via subcutaneously implanted electrodes. At day 15, animals were
killed and mitochondria were isolated from excised TA muscles to do
in vitro HRR measurements. Results: Metformin treatment decreased
PCr recovery rates in a dose-dependent manner in both healthy fa/+
and diabetic fa/fa rats. Whereas, the clinical dose of 30 mg/kg/day
had no signiﬁcant effect, PCr recovery rates were ~20% and ~50%
decreased at 100 and 300 mg/kg/day. HRR measurements showed a
similar dose-dependent effect of metformin on in vitromitochondrial
function.
Conclusion: Metformin treatment impairs in vivo skeletal muscle
oxidative capacity in rats in a dose-dependent manner. Since an
impairment of mitochondrial function has been implicated in the
pathogenesis of type 2 diabetes, our results would suggest the clinical
use of metformin to treat type 2 diabetes might need to be reevaluated.
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